Evidence mapPaperPMID 27047746Full record

ArticleFEBS open bio2016

Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.

Janine Krüger, Ernst Wellnhofer, Heike Meyborg, Philipp Stawowy, Arne Östman, Ulrich Kintscher, Kai Kappert

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Janine KrügerCenter for Cardiovascular Research/CCR Institute of Laboratory Medicine Clinical Chemistry and Pathobiochemistry Charité - Universitätsmedizin Germany.
Ernst WellnhoferDepartment of Medicine/Cardiology Deutsches Herzzentrum Germany.
Heike MeyborgDepartment of Medicine/Cardiology Deutsches Herzzentrum Germany.
Philipp StawowyDepartment of Medicine/Cardiology Deutsches Herzzentrum Germany.
Arne ÖstmanCancer Center Karolinska Karolinska Institutet Stockholm Sweden.
Ulrich KintscherCenter for Cardiovascular Research/CCR Institute of Pharmacology Charité - Universitätsmedizin Berlin Germany.
Kai KappertCenter for Cardiovascular Research/CCR Institute of Laboratory Medicine Clinical Chemistry and Pathobiochemistry Charité - Universitätsmedizin Germany.
Charité - Universitätsmedizin Berlin · DEDeutsches Herzzentrum der Charité · DEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance plays a crucial role in the development of type 2 diabetes. Insulin receptor signalling is antagonized and tightly controlled by protein tyrosine phosphatases (PTPs). However, the precise role of the PTP src homology 2 domain-containing phosphatase 1 (SHP-1) in insulin resistance has not been explored. Male C57BL/6J mice were fed a high-fat diet (HFD, 60% kcal from fat), to induce insulin resistance, or a low-fat diet (LFD, 10% kcal from fat) for 10 weeks. Afterwards, HFD-fed mice were pharmacologically treated with the SHP-1 (Ptpn6) inhibitor sodium stibogluconate and the broad spectrum pan-PTP inhibitor bis(maltolato)oxovanadium(IV) (BMOV). Both inhibitors ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance, which was not due to altered PTP gene expression. In parallel, phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt was enhanced, and both PTP inhibitors and siRNA-mediated SHP-1 downregulation resulted in an increased glucose uptake in vitro. Finally, recombinant SHP-1 was capable of dephosphorylating the ligand-induced tyrosine-phosphorylated insulin receptor. These results indicate a central role of SHP-1 in insulin signalling during obesity, and SHP-1 inhibition as a potential therapeutic approach in metabolic diseases.

Indexed as

bis(maltolato)oxovanadium(IV)insulin resistanceprotein tyrosine phosphatasesPTP inhibitionSHP‐1/Ptpn6sodium stibogluconate

Identifiers

PMID27047746
PMCPMC4794785
OpenAlexW2279273361

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.